This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

PRISMS study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) was a double-blind, placebo-controlled trial of interferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Patients had mild to moderate multiple sclerosis (EDSS scores 0 - 5.0).

Patients were randomised to 2 years of:

  • placebo
  • 22 mcg subcutaneously three times per week
  • 44 mcg subcutaneously three times pre week


  • 1) PRISMS Study Group. (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet, 352(7), 1498-504

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page